Detailed Study of the Kidney Cancer - Pipeline Review, H1 2016

Kidney Cancer (Renal Cell Cancer) - Pipeline Review, H1 2016 is a new market research publication announced by Reportstack. This report provides an overview of the Kidney Cancer (Renal Cell Cancer) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Kidney Cancer (Renal Cell Cancer), complete with analysis by stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Kidney Cancer (Renal Cell Cancer) and features dormant and discontinued projects.

To access full report with TOC, please visit Kidney Cancer (Renal Cell Cancer) - Pipeline Review, H1 2016

This report is built using data and information sourced from a proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. The profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

- The report provides a snapshot of the global therapeutic landscape of Kidney Cancer (Renal Cell Cancer)
- The report reviews pipeline therapeutics for Kidney Cancer (Renal Cell Cancer) by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report reviews key players involved Kidney Cancer (Renal Cell Cancer) therapeutics and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Kidney Cancer (Renal Cell Cancer)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Kidney Cancer (Renal Cell Cancer)
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies Mentioned

4SC AG AbbVie Inc. Acceleron Pharma, Inc. Advanced Cancer Therapeutics Advaxis, Inc. Advenchen Laboratories, LLC Alethia Biotherapeutics Inc. Altor BioScience Corporation Ambrx, Inc. Amgen Inc. Ampio Pharmaceuticals, Inc. Apcure SAS APEIRON Biologics AG arGEN-X BV Argos Therapeutics, Inc. ArQule, Inc. Arrowhead Pharmaceuticals, Inc. Astellas Pharma Inc. AstraZeneca Plc ATLAB Pharma SAS Aurigene Discovery Technologies Limited Bayer AG Berg LLC BIND Therapeutics, Inc. Bio-Cancer Treatment International Limited BIOCAD Bionomics Limited Bionovis SA Boehringer Ingelheim GmbH Boston Biomedical, Inc. Bristol-Myers Squibb Company Caladrius Biosciences, Inc. Calithera Biosciences, Inc. CASI Pharmaceuticals Inc. Celgene Corporation Cellceutix Corporation Celldex Therapeutics, Inc. Celltrion, Inc. Cellular Biomedicine Group, Inc. Cerulean Pharma, Inc. Chipscreen Biosciences Ltd Clonz Biotech Private Limited Coare Biotechnology, Inc. Coherus BioSciences, Inc. Corcept Therapeutics Incorporated Corvus Pharmaceuticals, Inc. Cytune Pharma SAS Dr. Reddy's Laboratories Limited Ecrins Therapeutics SAS EirGenix Inc. Eisai Co., Ltd. Eli Lilly and Company Esperance Pharmaceuticals, Inc. Exelixis, Inc. F. Hoffmann-La Roche Ltd. Gene Techno Science Co., Ltd. Genor BioPharma Co., Ltd. GenSpera, Inc. GlaxoSmithKline Plc Glycotope GmbH HEC Pharm Co., Ltd. Horizon Pharma Plc Hutchison MediPharma Limited Immatics Biotechnologies GmbH Immune Design Corp. Immunicum AB ImmunoFrontier, Inc. ImmunoGen, Inc. Immunomedics, Inc. Incuron, LLC Incyte Corporation Innate Immunotherapeutics Ltd Johnson & Johnson KAHR medical Ltd. Karyopharm Therapeutics, Inc. KineMed, Inc. Komipharm International Co., Ltd. Kyowa Hakko Kirin Co., Ltd. Lead Discovery Center GmbH Mabion SA MacroGenics, Inc. MaxiVAX SA MediaPharma s.r.l. MedImmune, LLC Medivation, Inc. Merck & Co., Inc. Merck KGaA Millennium Pharmaceuticals, Inc. Mirati Therapeutics Inc. Mirna Therapeutics, Inc. Molecular Partners AG Mologen AG Monopar Therapeutics LLC Mycenax Biotech Inc. NanoSmart Pharmaceuticals, Inc. Nektar Therapeutics NewLink Genetics Corporation Novartis AG NovaTarg Therapeutics, Inc Omeros Corporation OncBioMune Pharmaceuticals Inc. Oncobiologics, Inc. Oncolys BioPharma Inc. OncoMax Ono Pharmaceutical Co., Ltd. Panacea Biotec Limited Peloton Therapeutics, Inc. Pfizer Inc. Pharmicell Co., Ltd. Pivotal BioSciences, Inc. Plexxikon Inc. Prima BioMed Ltd. PsiOxus Therapeutics Limited Qu Biologics Inc. Recombio S.L Rexahn Pharmaceuticals, Inc. Sanofi Seattle Genetics, Inc. Selvita S.A. Sevion Therapeutics, Inc. Shanghai Henlius Biotech Co., Ltd. Sillajen Biotherapeutics Sorrento Therapeutics, Inc. Sumitomo Dainippon Pharma Co., Ltd. Syndax Pharmaceuticals, Inc. Synthon Holdings BV Taiwan Liposome Company, Ltd. Takeda Pharmaceutical Company Limited Tara Immuno-Oncology Therapeutics LLC Taris Biomedical LLC TC BioPharm Limited Teva Pharmaceutical Industries Ltd. Theravectys SA Threshold Pharmaceuticals, Inc. Tocagen Inc. TRACON Pharmaceuticals, Inc. TVAX Biomedical, Inc. Tyrogenex, Inc. United BioPharma, Inc. UroGen Pharmaceuticals, Ltd. Vascular Biogenics Ltd. Vault Pharma Inc. Vaxeal Holding SA ViiV Healthcare Limited Vyriad X4 Pharmaceuticals, Inc.

Contact:

Debora White

Manager - Marketing

debora@reportstack.com

Ph: +1-888-789-6604

Reportstack Market Research

###